Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2007, Article ID 12367, 3 pages
Clinical Study

Insights to Clinical Use of Serial Determination in Titers of Cyclic Citrullinated Peptide Autoantibodies

1Department of Integrated Japanese Oriental Medicine, School of Medicine, Gunma University, Maebashi, Gunma 371-8511, Japan
2Division of Japanese Oriental Medicine, Department of Internal Medicine, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama 930-8550, Japan
3Department of Japanese Oriental Medicine, Kanebo Memorial hospital, Kobe, Hyogo 652-0855, Japan
4Department of Japanese Oriental Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan

Received 14 December 2006; Revised 25 January 2007; Accepted 25 January 2007

Copyright © 2007 Toshiaki Kogure et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Anti-cyclic citrullinated peptide (CCP) antibody is a useful marker for the diagnosis and prognosis of rheumatoid arthritis (RA). Recently, clinical significance of follow-up in anti-CCP antibody titer has been pointed out. Thus, we investigated the serial determination in anti-CCP antibodies titer in RA patients. Six patients with RA, who were followed up for longer than 5 years, were assessed in anti-CCP antibodies and radiographs (Larsen score). Anti-CCP antibodies in frozen sera were measured using ELISA. As a result, 6 patients with RA were divided into two groups: one possessed high titers without variation, and the other was without high titers. Joint damage progressed during observation in 2 out of 3 patients with high anti-CCP titers in a retrospective assessment. In contrast, the RA patient, whose anti-CCP titer decreases although it had been high titer at baseline, did not show increase in the Larsen score. These findings suggest that it might be necessary to analyze changes in anti-CCP to predict the prognosis of joint destruction.